AnaptysBio (FRA:AN6) Margin of Safety % (DCF Earnings Based): N/A (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:AN6 AnaptysBio Inc FRA:AN6
64 GF Score
Price €55.00
GF Value €52.84
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is AnaptysBio Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

AnaptysBio's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

FRA:AN6 vs ABSI, TSHA, RXRX: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, AnaptysBio's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AnaptysBio Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AnaptysBio's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where AnaptysBio's Margin of Safety % (DCF Earnings Based) falls into.


FRA:AN6
64GF Score
AnaptysBio Inc FRA:AN6
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is AnaptysBio (FRA:AN6) Overvalued in 2026?

Based on GuruFocus' analysis, AnaptysBio stock appears to be overvalued. The current stock price of €55.00 is trading 4.1% above its estimated GF Value™ of €52.84. GuruFocus considers AnaptysBio to be Fairly Valued.

Key valuation signals for FRA:AN6:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €52.84 vs. price of €55.00 (4.1% above fair value)
  • GF Score™: 64/100 with 5 warning signs

No single metric tells the full story. See the FRA:AN6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AnaptysBio Business Description

Other Exchanges ANAB:USA0HFQ:UK
Address 10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
64GF Score

Get the complete analysis for FRA:AN6

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€55.00
Price
€52.84
GF Value